<!doctype html><html lang="en"><head><meta charset="utf-8"> <title>Life after Eroom’s law - Refoundable</title> <meta name="viewport" content="width=device-width,initial-scale=1,viewport-fit=cover"> <meta name="description" content="A conversation with Jack Scannell PhD on the end of Eroom’s law, the future of drug R&amp;D, and the secrets behind the science of drug discovery."> <meta name="theme-color" content="#061E29"> <link rel="alternate" href="/feed.xml" type="application/atom+xml"> <link rel="apple-touch-icon" href="/apple-touch-icon.png"><link rel="icon" href="/favicon.png" type="image/png"><link rel="icon" href="data:image/svg+xml;utf8,%3Csvg%20width%3D'256'%20height%3D'256'%20xmlns%3D'http%3A%2F%2Fwww.w3.org%2F2000%2Fsvg'%3E%3Cg%20fill%3D'none'%20fill-rule%3D'evenodd'%3E%3Cpath%20fill%3D'%23061E29'%20d%3D'M0%200h256v256H0z'%2F%3E%3Cpath%20d%3D'M113.2%20113H87V63.4H136c10.3%200%2020.9.2%2029.9%206a34.8%2034.8%200%200114.8%2029c0%2013.2-7.7%2025.4-20.2%2030l26.9%2065h-30L134%20133.9H73l-15.6-19.1h70.7c5.7%200%2011.9.5%2016.8-2.4%204.5-2.7%206.9-8.2%206.9-13.3%200-4.6-2.8-9.6-6.7-12-4.6-2.9-12.5-2.2-17.6-2.2h-14.4v28zm1%2022.7v44.2H86.8v-44.2H114z'%20fill%3D'%23FFF'%2F%3E%3C%2Fg%3E%3C%2Fsvg%3E" sizes="any" type="image/svg+xml"><link rel="mask-icon" href="/mask-icon.svg" color="#061E29"> <link rel="manifest" href="/manifest.json"> <style>:root{--fontstack-prefix:-apple-system,BlinkMacSystemFont,;--fontstack-sans-serif:"Helvetica Neue",sans-serif;--fontstack-serif:Georgia,serif;--fontstack-monospace:Menlo,Consolas,monospace;--fontstack-default:var(--fontstack-prefix) var(--fontstack-sans-serif);--font-size:1.6vw;--font-features:"halt","ss01","ss02";--line-height:calc(20 / 14);--heading-letter-spacing:-.04em;--breakpoint-lg:1600px;--breakpoint-md:1080px;--breakpoint-sm:640px;--breakpoint-xs:400px;--space-lg:24vw;--space-md:8vw;--space-sm:4vw;--space-xs:1.2vw;--border-lg:4px;--border-md:2px;--border-sm:1px;--link-color:#03549b;--background-color:#fff;--text-color:#000;--code-color:#3914b3;--nav-padding:.75vmax;--nav-item-space:1.4vmax}*,::after,::before{padding:0;margin:0;box-sizing:border-box}html{font-size:100%;-webkit-text-size-adjust:none;-ms-text-size-adjust:none;text-size-adjust:none;text-rendering:optimizelegibility;image-rendering:optimizequality;-webkit-font-smoothing:antialiased;-moz-osx-font-smoothing:grayscale;background:var(--bg-color)}body{--space-body:var(--space-lg);padding-top:0;padding-bottom:0;padding-left:var(--space-body);padding-right:var(--space-body);margin:0 auto 0;font-family:var(--fontstack-default);font-size:var(--font-size);font-feature-settings:var(--font-features);line-height:var(--line-height);hanging-punctuation:first allow-end;color:var(--text-color);background:var(--bg-color);-webkit-transition:all .2s ease;transition:all .2s ease}@media (max-width:1080px){body{--space-body:var(--space-md);font-size:calc(var(--font-size) * 1.4)}}@media (max-width:640px){body{--space-body:var(--space-sm);font-size:calc(var(--font-size) * 2.4)}}@media (max-width:400px){body{font-size:calc(var(--font-size) * 3.2)}}a{color:var(--text-color);text-decoration:none;-webkit-transition:color .5s ease,border-color .5s ease,background .5s ease,opacity 1.5s ease;transition:color .5s ease,border-color .5s ease,background .5s ease,opacity 1.5s ease}a:focus,a:hover{-webkit-transition:color .1s ease,border-color .1s ease,background .1s ease,opacity .1s ease;transition:color .1s ease,border-color .1s ease,background .1s ease,opacity .1s ease;text-decoration:underline}hr,img{border:0}::-webkit-input-placeholder{color:var(--text-color);opacity:.2}::-moz-placeholder{color:var(--text-color);opacity:.2}:-ms-input-placeholder{color:var(--text-color);opacity:.2}::-ms-input-placeholder{color:var(--text-color);opacity:.2}:focus::-webkit-input-placeholder{color:var(--link-color)}:focus::-moz-placeholder{color:var(--link-color)}:focus:-ms-input-placeholder{color:var(--link-color)}:focus::-ms-input-placeholder{color:var(--link-color)}.navigation{padding-top:var(--nav-padding);padding-bottom:var(--nav-padding);margin-right:calc(var(--nav-item-space) * -1);margin-left:calc(var(--nav-item-space) * -1);font-size:90%;font-weight:700}.navigation li{display:inline-block;line-height:2}.navigation li a{padding:.5em var(--nav-item-space)}.navigation li a:focus,.navigation li a:hover{color:var(--link-color);text-decoration:none}.content{margin-bottom:16vmin}.content::after,.content::before{display:table;content:""}.content::after{clear:both}.content article>:last-child{margin-bottom:0!important}.content a{font-weight:700}.content a:has(>code){-webkit-text-decoration-color:var(--code-color);text-decoration-color:var(--code-color)}.content p{margin-bottom:1.6rem;line-height:calc(var(--line-height) * 1.2)}.content h2,.content h3{margin:10vmin 0 1rem;font-size:72%;font-weight:400;opacity:.5}.content ol,.content ul{margin-bottom:1.8rem;list-style:none;counter-reset:list}@media (max-width:640px){.content ol,.content ul{margin-left:1em}}.content ol li,.content ul li{line-height:calc(var(--line-height) * 1.2)}.content ol li::before,.content ul li::before{position:absolute;display:-webkit-box;display:flex;-webkit-box-pack:end;justify-content:flex-end;width:4em;margin-top:0;margin-left:-4em;text-align:right;opacity:.4;pointer-events:none}.content ul li::before{content:"-";padding-right:.5em}.content ol li::before{counter-increment:list;content:counter(list) ".";padding-right:.25em}.content img{--space-deco:var(--space-md);display:block;width:calc(100% + var(--space-deco) * 2);margin-left:calc(var(--space-deco) * -1);margin-right:calc(var(--space-deco) * -1);margin-bottom:1.8rem}@media (max-width:1080px){.content img{--space-deco:var(--space-md)}}@media (max-width:640px){.content img{--space-deco:var(--space-sm)}}.content hr::before{display:block;content:'';width:3px;height:3px;margin:2em auto;border-radius:50%;background:var(--text-color);box-shadow:24px 0 0 0 var(--text-color),-24px 0 0 0 var(--text-color)}.content sup{font-size:75%}.footnotes{font-size:80%}.footnotes::before{display:block;content:'';width:3px;height:3px;margin:2em auto;border-radius:50%;background:var(--text-color);box-shadow:24px 0 0 0 var(--text-color),-24px 0 0 0 var(--text-color)}.footer{padding:0 0 16vmin;margin-right:calc(var(--nav-item-space) * -1);margin-left:calc(var(--nav-item-space) * -1);font-size:80%;text-transform:lowercase}.footer ul li{display:inline-block;line-height:1.8}.footer ul li a{padding:.5em var(--nav-item-space)}@media print{*,::after,::before{background:0 0!important;color:#000!important;box-shadow:none!important;text-shadow:none!important}body{padding:10mm!important;margin:0!important;font-size:calc(var(--font-size) * 1.35)}a,a:visited{text-decoration:none}img{page-break-inside:avoid}img{max-width:100%!important}h2,h3,p{orphans:3;widows:3}h2,h3{page-break-after:avoid}.footer,.navigation{display:none}}:root{--rdmz-h:var(--code-color-h, 253.962264151);--rdmz-s:var(--code-color-s, 79.8994974874%);--rdmz-l:var(--code-color-l, 39.0196078431%)}body,html{max-width:100%;overflow-x:hidden}body{height:100%;width:100%;margin:0}.content{margin-bottom:0}.content h2,.content h3{opacity:1;margin:0}.content ul li::before{content:"\2022"}.content hr::before{margin:0 auto;height:0;width:0}.txt-wrap{white-space:nowrap}.content a,a,figcaption,ol li,p,span,ul li{font-weight:var(--reg-w)}.essay .head,.essay .rubric,.essay .title,.essay h2,.essay h2 a,.essay h3{font-weight:var(--sem-w)!important}.essay .cta,.essay .cta a{font-weight:var(--reg-w)!important}a:focus::-webkit-input-placeholder{color:var(--m-blue)}a:focus::-moz-placeholder{color:var(--m-blue)}a:focus:-ms-input-placeholder{color:var(--m-blue)}a:focus::-ms-input-placeholder{color:var(--m-blue)}.essay .title,.essay h2{letter-spacing:-.04em}.essay .head,.essay h3{letter-spacing:-.065em}.essay .cta,.essay .cta a,.essay ol li,.essay p{letter-spacing:-.025em}.navigation{font-weight:var(--reg-w);text-align:center;letter-spacing:-.025em;margin:var(--nil) var(--full-wid);background-color:var(--x-black);padding:0}.navigation li{padding:.5em 0}.navigation li a{color:var(--xx-white)}.navigation li a:focus,.navigation li a:hover{color:var(--xm-silver)!important}.navigation #logomark a svg{width:1.2em;height:1.2em;margin-bottom:-.15rem}.rg-aro{border-right:1px solid;border-bottom:1px solid}.bo-aro{border-right:1.5px solid;border-bottom:1.5px solid}.sh-aro{height:.4em;width:.4em;display:inline-block;color:var(--m-blue)}.tp-aro{height:.5em;width:.5em;display:inline-block;color:var(--xxx-silver)}.d-aro{-webkit-transform:rotate(45deg);transform:rotate(45deg)}.u-aro{-webkit-transform:rotate(-135deg);transform:rotate(-135deg)}.ext-aro-bs{position:relative;display:inline-block;vertical-align:middle;color:var(--m-blue);box-sizing:border-box}.ext-aro-bs:after,.ext-aro-bs:before{content:"";box-sizing:border-box}.ext-aro-fo{width:.45em;height:.45em;border-width:1px 1px 0 0;border-style:solid;margin:0 0 1px .3em}.ext-aro-fo:before{right:0;top:-1px;position:absolute;height:1px;box-shadow:inset 0 0 0 32px;-webkit-transform:rotate(-45deg);transform:rotate(-45deg);width:.7em;-webkit-transform-origin:right top;transform-origin:right top}.fn-ext-lnk{margin-left:.15em}.essay-nav{font-weight:var(--reg-w);font-size:82%;text-align:center;letter-spacing:-.025em;margin:var(--nil) var(--full-wid) -5vh;padding:0;z-index:1;border-bottom:1px solid var(--x-silver)}.essay-nav ul{margin-bottom:0}.essay-nav ul li{display:inline-block;line-height:2;padding:.5em 0}.essay-nav ul li:before{display:none}.essay-nav a.sticky-btn{font-weight:var(--reg-w);padding:.3em 1em;margin:0 1em;color:var(--l-black);text-decoration:none;-webkit-transition:none;transition:none}.essay-nav a.sticky-btn:hover{opacity:.7}.essay{counter-reset:count-fn 0 count-qst 0;margin:0 auto}.essay a{color:var(--m-blue)}.essay ol li,.essay p{line-height:1.35;color:var(--xm-black)}.essay ol li{margin-bottom:.3em}.essay hr{padding:0 0 8vw}.essay .essay-header{padding:8vw 0}.essay .callout{text-align:center}.essay .callout .title{color:var(--xm-silver);text-decoration:none;margin:0}.essay .callout .head{line-height:1;color:var(--x-black)!important;margin:0 0 .3em}.essay .callout .deck{margin:0 auto}.essay .callout .byline{display:none}.essay .callout .cta{margin:0;padding-top:.7rem}.essay .callout .cta a{color:var(--m-blue)!important;font-weight:var(--reg-w)!important;padding-right:.2rem;padding-bottom:.2em;margin-left:1%}.essay .callout .po-aro{margin-bottom:.2em;margin-left:.2em}.essay .callout .rubric{margin:0 auto -1.5em;color:var(--m-accent);position:relative;top:-1.8em;text-transform:uppercase}.essay .section-headings{position:relative;padding-top:8vw!important}.essay .section-headings h2 a{color:var(--xm-silver);text-decoration:none;padding:8vw 0 0}.essay .section-headings h3{line-height:1;color:var(--x-black)!important;max-width:65%}.essay figure figcaption{font-weight:var(--reg-w);color:var(--m-gray);text-align:center;padding-top:.5rem;margin:auto}.essay figure .credits{color:var(--x-silver);font-size:95%}.essay figure .credits-blk{display:block}.essay .qst{margin-top:-1em;margin-bottom:.7em;padding-top:2.2em;font-weight:var(--med-w)}.essay .qst::before{color:var(--m-gray);counter-increment:count-qst;content:counter(count-qst) ".";position:absolute;display:-webkit-box;display:flex;-webkit-box-pack:end;justify-content:flex-end;width:4em;margin-top:0;margin-left:-4em;text-align:right;opacity:.4;pointer-events:none;padding-right:.25em}.essay .qst-lnk{padding:.2em .3em!important;margin-right:-1.5em}.essay .qst-lnk svg{fill:var(--m-gray);opacity:.4;vertical-align:middle}.essay .fn-btn{background-color:var(--l-silver);position:relative;margin-left:.3em;color:var(--m-gray);font-weight:var(--sem-w);font-size:90%;text-decoration:none}.essay .fn-btn:hover{background-color:var(--xl-silver)}.essay .fn-btn:focus{outline:0}.essay .fn-btn-top{padding:.25em 1em .35em!important;top:.35em;margin-left:.2em}.essay .fn-btn-bot{padding:.35em .8em .3em!important;margin-left:.5em;top:.1em}.essay sup{padding-top:25vh;margin-top:-25vh}.essay .footnotes{font-size:inherit;padding-bottom:2.2vw;border-top:1px solid var(--m-silver);padding-top:2em}.essay .footnotes:before{display:none}.essay .footnotes p{line-height:1.5}.essay .footnotes ol li{display:-webkit-box;display:flex}.essay .footnotes ol li:before{color:var(--m-gray);position:relative;display:inline-block;counter-increment:count-fn;content:counter(count-fn) "."}.footer{text-align:center}.footer a,.footer p{margin:0 .2em;padding:0 .1em!important}.footer a,.footer p,.footer ul{display:inline-block;text-transform:capitalize}.footer ul li:before{content:" "!important;display:none}.footer .return-top{text-align:center;margin-bottom:6vh}.footer .return-top a{font-size:130%;text-decoration:none;padding:.15em .85em .25em!important;border-radius:7px;margin-left:.2em}.footer .return-top a:hover{text-decoration:none}.footer-light{padding:0;margin:4vh auto 3vh}.footer-light a,.footer-light p{color:var(--xxx-silver)}.footer-light .return-top a{background-color:var(--l-silver)}.footer-light .return-top a:hover{background-color:var(--xl-silver)}:root{--reg-w:400;--med-w:500;--sem-w:600;--lg-rubric:70%;--lg-title:210%;--lg-head:395%;--lg-deck:140%;--lg-cta:130%;--lg-bghead:440%;--lg-subhead:160%;--lg-bgcta:150%;--md-rubric:80%;--md-title:240%;--md-head:450%;--md-deck:160%;--md-cta:150%;--md-bghead:450%;--md-subhead:180%;--md-bgcta:170%;--sm-rubric:90%;--sm-title:230%;--sm-head:370%;--sm-deck:180%;--sm-cta:170%;--sm-bghead:430%;--sm-subhead:200%;--sm-bgcta:180%;--xs-rubric:65%;--xs-title:170%;--xs-head:280%;--xs-deck:130%;--xs-cta:130%;--xs-bghead:330%;--xs-subhead:155%;--xs-bgcta:140%;--lg-nav:90%;--md-nav:120%;--sm-nav:140%;--xs-nav:110%;--lg-txt:130%;--md-txt:150%;--sm-txt:170%;--xs-txt:130%;--lg-fn:100%;--mo-fn:80%;--lg-fig:90%;--md-fig:115%;--sm-fig:130%;--xs-fig:95%;--lg-not:110%;--md-not:140%;--sm-not:160%;--xs-not:120%;--lg-foo:80%;--md-foo:105%;--sm-foo:120%;--xs-foo:90%;--xx-black:#0d0d0d;--x-black:#111;--xm-black:#222;--m-black:#272727;--l-black:#333;--xl-black:#444;--m-gray:#555;--m-blue:#03549b;--xx-white:#fff;--xxx-silver:#898989;--xx-silver:#aaa;--x-silver:#bbb;--bf-silver:#bfbfbf;--xm-silver:#cfcfcf;--m-silver:#ddd;--l-silver:#eee;--xl-silver:#e7e7e7;--m-accent:#805e03;--vl-accent:#f6f6f6;--nil:0;--full-wid:-50%;--space-lg:21vw}@font-face{font-family:Barlow;font-style:normal;font-weight:400;src:local("Barlow Regular"),local("Barlow-Regular"),url(https://fonts.gstatic.com/s/barlow/v4/7cHpv4kjgoGqM7E_DMs5ynghnQ.woff2) format("woff2");unicode-range:U+0000-00FF,U+0131,U+0152-0153,U+02BB-02BC,U+02C6,U+02DA,U+02DC,U+2000-206F,U+2074,U+20AC,U+2122,U+2191,U+2193,U+2212,U+2215,U+FEFF,U+FFFD}@font-face{font-family:Barlow;font-style:italic;font-weight:400;src:local("Barlow Italic"),local("Barlow-Italic"),url(https://fonts.gstatic.com/s/barlow/v4/7cHrv4kjgoGqM7E_Cfs7wH8Dnzcj.woff2) format("woff2");unicode-range:U+0000-007F}@font-face{font-family:Barlow;font-style:normal;font-weight:500;src:local("Barlow Medium"),local("Barlow-Medium"),url(https://fonts.gstatic.com/s/barlow/v4/7cHqv4kjgoGqM7E3_-gs51ostz0rdg.woff2) format("woff2");unicode-range:U+0000-007F}@font-face{font-family:Barlow;font-style:normal;font-weight:600;src:local("Barlow SemiBold"),local("Barlow-SemiBold"),url(https://fonts.gstatic.com/s/barlow/v4/7cHqv4kjgoGqM7E30-8s51ostz0rdg.woff2) format("woff2");unicode-range:U+0000-00FF,U+0131,U+0152-0153,U+02BB-02BC,U+02C6,U+02DA,U+02DC,U+2000-206F,U+2074,U+20AC,U+2122,U+2191,U+2193,U+2212,U+2215,U+FEFF,U+FFFD}@font-face{font-family:system-ui;font-style:normal;font-weight:400;src:local(".SFNSText-Regular"),local(".HelveticaNeueDeskInterface-Regular"),local(".LucidaGrandeUI"),local("Segoe UI"),local("Ubuntu"),local("Roboto-Regular"),local("DroidSans"),local("Tahoma")}@font-face{font-family:system-ui;font-style:normal;font-weight:600;src:local(".SFNSText-Medium"),local(".HelveticaNeueDeskInterface-MediumP4"),local(".LucidaGrandeUI"),local("Segoe UI Semibold"),local("Ubuntu Medium"),local("Roboto-Medium"),local("DroidSans-Bold"),local("Tahoma Bold")}:root{--font-size:1.3vw;--fontstack-prefix:'Barlow','Barlow-Local',system-ui;--fontstack-sans-serif:'Barlow','Barlow-Local',system-ui,sans-serif}html{font-family:Barlow,Barlow-Local,system-ui,sans-serif}@media screen and (max-width:799px){.navigation li{padding:.6em .3em;margin:0 .5em 0 0}.essay-nav{display:none}.essay{max-width:100%}.essay p{max-width:94%;line-height:1.4}.essay ol,.essay p{margin-left:3%;margin-bottom:1.2em}.essay ol{max-width:97%;margin-left:0!important}.essay ol li{margin-left:1.5em;line-height:1.4}.essay .callout{margin:0 auto 6vw!important;padding:15% 0 20%}.essay .callout .cta a{letter-spacing:-.025em}.essay .section-headings{margin-bottom:8vw;left:3%;max-width:100%}.essay figure{margin:11% auto 10%}.essay figure img{width:110%;margin-bottom:0}.essay figure figcaption{max-width:95%}.essay .qst{margin-top:1.2em}.essay .qst::before{margin-top:-1.8em;margin-left:0;font-size:80%;font-weight:var(--sem-w);background-color:#dfdfdf;content:counter(count-qst);width:2em;-webkit-box-pack:center;justify-content:center;text-align:center;padding-right:0}.essay .fn-btn{border-radius:4px}.essay .footnotes{margin-top:10vw}.essay .footnotes ol li::before,.essay .footnotes p{font-size:var(--mo-fn)}.essay .footnotes p{margin-left:0;max-width:90%}.essay .footnotes ol li{margin-left:0;padding-top:11vh;margin-top:-11vh}.essay .footnotes ol li:before{margin-top:.05em;margin-left:-2.3em}.essay #deck-mis{max-width:100%}.footer ul{margin-left:0}}@media screen and (max-width:400px){.navigation{font-size:var(--xs-nav)}.essay .rubric{font-size:var(--xs-rubric)}.essay .title,.essay h2{font-size:var(--xs-title)!important}.essay .head,.essay h3{font-size:var(--xs-head)}.essay .deck{font-size:var(--xs-deck)}.essay .cta{font-size:var(--xs-cta)}.essay ol li,.essay p{font-size:var(--xs-txt)}.essay figure{font-size:var(--xs-fig)}.footer{font-size:var(--xs-foo)}}@media screen and (min-width:401px) and (max-width:639px){.navigation{font-size:var(--sm-nav)}.essay .rubric{font-size:var(--sm-rubric)}.essay .title,.essay h2{font-size:var(--sm-title)!important}.essay .head,.essay h3{font-size:var(--sm-head)!important}.essay .deck{font-size:var(--sm-deck)!important}.essay .cta{font-size:var(--sm-cta)}.essay ol li,.essay p{font-size:var(--sm-txt)}.essay figure{font-size:var(--sm-fig)}.footer{font-size:var(--sm-foo)}}@media screen and (min-width:640px) and (max-width:799px){.navigation{font-size:var(--md-nav)}.essay .rubric{font-size:var(--md-rubric)}.essay .title,.essay h2{font-size:var(--md-title)!important}.essay .head,.essay h3{font-size:var(--md-head)}.essay .deck{font-size:var(--md-deck)!important}.essay .cta{font-size:var(--md-cta)}.essay ol li,.essay p{font-size:var(--md-txt);margin-left:0}.essay figure{font-size:var(--md-fig)}.footer{font-size:var(--md-foo)}.navigation li{margin:0 2em 0}.essay{max-width:95%}.essay ol li{margin-left:0}.essay p{max-width:100%}.essay .section-headings{margin-bottom:6vw;left:0}.essay figure img{width:100%;margin:0 auto;border-radius:20px}.essay figure figcaption{max-width:80%}.essay .qst{margin-top:-1em}.essay .qst::before{margin-top:0;margin-left:-4em;font-size:100%;font-weight:var(--reg-w);background-color:transparent;width:4em;content:counter(count-qst) ".";-webkit-box-pack:end;justify-content:flex-end;text-align:right;padding-right:.25em}.essay .fn-btn{border-radius:4px}.essay .footnotes{margin:10vw auto 0 -1.75em;max-width:100%}.essay .footnotes ol,.essay .footnotes p{max-width:100%;width:100%}.essay .footnotes ol li:before{margin-left:0;width:1.5em}.essay #deck-mis{max-width:85%}}@media screen and (min-width:800px){.navigation{font-size:var(--lg-nav)}.essay .rubric{font-size:var(--lg-rubric)}.essay .title,.essay h2{font-size:var(--lg-title)!important}.essay .head,.essay h3{font-size:var(--lg-head)}.essay .deck{font-size:var(--lg-deck)!important}.essay .cta{font-size:var(--lg-cta)}.essay ol li,.essay p{font-size:var(--lg-txt)}.essay figure{font-size:var(--lg-fig)}.essay .footnotes ol li,.essay .footnotes p{font-size:var(--lg-fn)}.footer{font-size:var(--lg-foo)}.navigation li{padding:.5em 0}.navigation li a{padding:.3em 1em;margin:0 2.5em}.navigation #logomark{margin-left:3%}.essay-nav{display:none}.essay{max-width:95%}.essay ol li,.essay p{max-width:86%;margin-left:5%}.essay .callout{margin:0 auto!important;padding:4% 0 10%}.essay .section-headings{margin-bottom:5vw;left:-1.5em}.essay figure{margin:10% auto 9%}.essay figure img{width:100%;max-width:1200px;margin:0 auto;border-radius:20px}.essay figure figcaption{max-width:65%}.essay .fn-btn{border-radius:7px}.essay .footnotes{max-width:100%;margin:8vw auto 0 .9em}.essay .footnotes ol li{padding-top:9vh;margin-top:-9vh;max-width:100%;margin-left:0}.essay .footnotes ol li p{margin-left:0}.essay .footnotes ol li:before{margin-left:-2.75em}.essay #deck-mis{max-width:80%}}@media screen and (min-width:1080px){.essay-nav{display:block}.essay-nav-scroll{position:fixed!important;width:100%!important;top:0;left:50%;-webkit-transition:background-color .5s cubic-bezier(.28,.11,.32,1);transition:background-color .5s cubic-bezier(.28,.11,.32,1);border-bottom-color:var(--xl-black)!important;background-color:var(--l-black)!important}.essay-btn-scroll{color:var(--xl-silver)!important}.essay{max-width:93%}.essay ol li,.essay p{max-width:91%}.essay figure figcaption{max-width:70%}.essay #deck-mis{max-width:80%}}</style> <link href="https://fonts.googleapis.com/css?family=Barlow:400,400i,500,600&amp;display=swap" rel="stylesheet"> <link rel="canonical" href="https://refoundable.com/scannell"> <meta property="og:type" content="article"> <meta property="og:site_name" content="Refoundable"> <meta property="og:title" content="Life after Eroom’s law"> <meta property="og:url" content="https://refoundable.com/scannell"> <meta property="og:description" content="A conversation with Jack Scannell PhD on the end of Eroom’s law, the future of drug R&amp;D, and the secrets behind the science of drug discovery."> <meta property="og:image" content="https://refoundable.com/assets/img/og-iconic.png"> <meta name="twitter:card" content="summary_large_image"> <meta name="twitter:site" content="@refoundable"> </head><body><nav id="top" class="navigation"> <ul> <li id="logomark"> <a href="/"><svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 200 200"><path d="M85.7 76H45.2V0h75.6c16 0 32.2.3 46.1 9.1a53.5 53.5 0 0122.8 44.7 48.4 48.4 0 01-31.2 46.1L200 200h-46l-36.3-91.7H24L0 78.8h108.9c8.7 0 18.1.8 25.8-3.7a24.2 24.2 0 0010.5-20.5c0-7-4.2-14.7-10.3-18.3-7-4.5-19.2-3.4-27-3.4H85.6v43zm1.4 35v68.1h-42v-68h42z" fill="#FFF" fill-rule="evenodd"></path></svg></a> </li> <li> <a href="/mission">Mission</a> </li> <li> <a href="/soon">Research</a> </li> <li> <a href="/about">About</a> </li> </ul> </nav> <main class="content" role="main"> <script>window.onscroll=function(){window.addEventListener("scroll",stickyNav)}</script> <nav id="sticky-nav" class="essay-nav"> <ul> <li><a class="sticky-btn" href="#s1">Introduction</a></li> <li><a class="sticky-btn" href="#s2">Discovery</a></li> <li><a class="sticky-btn" href="#s3">Decline</a></li> <li><a class="sticky-btn" href="#s4">Alchemy</a></li> </ul> </nav> <article class="essay"> <div class="essay-header"> <div class="callout"> <div class="meta"> <div class="rubric">Interview&nbsp;&nbsp;•&nbsp;&nbsp;March 6, 2020</div> <div class="title">Secrets</div> </div> <h1 class="head">Life after<br>Eroom’s law.</h1> <p class="deck" id="deck-mis">A conversation with Jack Scannell PhD on the end of Eroom’s law, the future of drug R&amp;D, and the secrets behind&nbsp;the science of drug discovery.</p> <div class="byline"> <span>By John Strider</span><span>&nbsp;|&nbsp;</span> <span>Refoundable</span> </div> <div class="cta"><a href="#s1">Introduction</a><div class="rg-aro sh-aro po-aro d-aro"></div></div> </div> </div>  <div class="section-headings"> <h2><a id="s1">Introduction</a></h2> <h3>Looking past<br>the end.</h3> </div> <p>There are three ways people like to justify the failure to look for new and valuable secrets in our time: It’s too hard, it takes too long, or it’s too dangerous to try.</p> <p>As these three can never be definitive, they inevitably give rise to a fourth excuse, one that is best encapsulated by John Horgan in <em>The End of Science</em>, which can be summed up in three words: It’s all over.</p> <p>Yet, can we truly believe that we’re at the end of Science? Have we run out of things to discover? Or is it merely a failure of our imagination?</p> <p>Whichever way you come down on these questions, it’s unlikely that we can settle this debate today once and for all, so let’s flag the issue and press on to make an observation that could suggest an indirect way forward.</p> <p style="font-weight:500">End games</p> <p>One cultural precursor to Horgan’s theory is Francis Fukuyama’s <em>The End of History</em>, which came out less than a year after the end of the Cold War, when optimism abounded about the inevitable spread of liberal democracy to all corners of the world.</p> <p>Fukuyama may have been channeling the zeitgeist of his time, but with the benefit of hindsight, we can see that anyone too eager to believe in that theory was caught woefully unprepared when the new world order it promised collapsed into a heap of chaos at the turn of the century, on a fateful September morning.</p> <p>If Fukuyama’s great proclamation could be routed by a band of suicide-murderers who presumably didn’t subscribe to <em>The New York Times</em>, then is it unreasonable to assume that Horgan’s theory about the closing of Science could still be turned on its head?</p> <p>Certainly one scenario to underscore is that the unsettling proof may yet emerge in the far east, far beyond the bounds of the western world, where nations are driven to extreme lengths by ruthless competition, and people still have great expectations of scientific <span class="txt-wrap">progress.<sup><a href="#fn1" id="r1" class="fn-btn fn-btn-top">1</a></sup></span></p> <p>If we don’t want to be caught unprepared this time, then even by the low standards of self-preservation, we cannot keep excusing our failure to try harder. The first step out of our long deep rut is to believe that we can find new secrets for ourselves.</p> <p style="font-weight:500">Bottoms up</p> <p>Immediately, however, we run into an issue. Where should our search for secrets begin?</p> <p>Too many people make the rational decision to look for secrets in the easy areas that have seen the most progress over the last half-century, so a counter-intuitive approach at this point might be to start with the technology areas worst hit by neglect, stagnation and rising costs, and figure out how to restart their <span class="txt-wrap">progress.<sup><a href="#fn2" id="r2" class="fn-btn fn-btn-top">2</a></sup></span></p> <p>Take healthcare for example. While computers got faster and cheaper every year over the last five decades, healthcare costs rose faster than inflation, and average life expectancy grew by a measly eight years since <span class="txt-wrap">1970.<sup><a href="#fn3" id="r3" class="fn-btn fn-btn-top">3</a></sup></span></p> <p>Yet, unlike other stagnating technology areas like defense or nuclear energy, we can get most people to agree that healthcare is both deeply broken and crucial to fix, so on the whole, less people might try to stop us if we start there.</p> <p>Still, a full frontal attack on the healthcare question is ill-advised, as the sheer scale of the field amplifies its inertia a hundredfold, so let’s take a lesson from the startup world, and focus on breaking through in one key area.</p> <p>Our ideal target is a field where the more progress we could make, the less effort we’d have to put in to discover new secrets. Certainly, this was how people thought about pharmaceuticals in the past.</p> <p>The promise was that you could unlock the secrets of biochemistry and use them to concoct all sorts of enhancements, from chemical food pills to the elixir of immortality.</p> <p>Instead, the pharma industry today looks, if anything, like it’s moving in the opposite direction. Every day seems to bring even less clarity on how complex biology works, and the cures are only getting only harder to find, so we might ask: what went wrong?</p> <p>At first glance, it’s hard to know exactly what’s going on, as the industry puts out an overwhelming torrent of abstruse data to tell any bullish or bearish story you like. Fortunately for us, however, the field does have one robust measure of progress that can cut the hype cycle short.</p> <p>It’s called Eroom’s law, and the name is already saying a lot. It’s literally an ironic backward spelling of Moore’s law, the equivalent benchmark of progress in the computer industry, so it seems like the most fitting place to start.</p> <p style="font-weight:500">Scraping the bottom</p> <p>Eroom’s law is the observation that the cost of developing a new drug roughly doubled every nine years from 1950 through the 2010. All in all, it shows an 80 fold drop in the productivity of drug R&amp;D.</p> <p>In a way, it’s hard to say which is worse, the staggering decline or the fact that it went on for six decades. Either way, as the sum total of our effort to look for life-saving secrets, Eroom’s law leaves no doubt that our ability to explore the frontier has atrophied catastrophically.</p> <figure> <img class="ful-img" alt="Eroom's law shows the staggering decline in drug R&amp;D productivity" id="img-eroom-1" src="/assets/img/buf.png" data-echo="/assets/img/eroom-1.png"> <figcaption id="cap-eroom-1">9 out of 10 drugs never make it to market, while a successful drug that cost $100M to develop in the 1960s came to cost over $1 billion four decades later.<span class="credits credits-blk">Jack Scannell</span></figcaption> </figure> <p>Although some aspects of this trendline had been known since the 1980s, Eroom’s law was formally articulated in a 2012 paper published in <em>Nature</em>, written by four co-authors led by Jack Scannell.<sup><a href="#fn4" id="r4" class="fn-btn fn-btn-top">4</a></sup></p> <p>In a field plagued by narrow specialization, Jack Scannell is something of a renaissance man, having seen the industry from a distance and up close while working in drug research, private consulting, pharma and biotech investing, and policy advising.</p> <p>As a result, Eroom’s law is far from his only contribution to the field. In the course of investigating how such a disturbing trend could hold for so long, Jack came to some troubling conclusions about the validity of the modern scientific methods used in drug discovery.</p> <p>The top executives at major pharma companies, who deploy billions of dollars in R&amp;D every year, and most of the industry will repeatedly say that the low productivity of drug R&amp;D is due to the exhaustion of easy targets—an oversimplification, no doubt, but still only an elaborate way of saying that the search is too hard.</p> <p>Jack, however, believes that the problem isn’t that we’re running out of easy pickings, but that we’re not using the proper search methods to find better drug candidates in the first place. In other words, we’re looking in all the wrong places at great expense, and predictably turning up nothing.<sup><a href="#fn5" id="r5" class="fn-btn fn-btn-top">5</a></sup></p> <p>You can only run with this flawed strategy for so long, and after six decades of poor returns, investors have concluded that it’s better for the industry to scale back its R&amp;D investing and shut down research labs. As this cycle of bloodletting picks up pace, Eroom’s law is finally coming to a bitter end.</p> <p>We sit down with Jack Scannell to assess the record, discuss what lies ahead, and explore the secrets behind the science of drug discovery.</p> <div class="footnotes"> <ol> <li id="fn1"> <p>Although the ivory tower can be a very insular place, the outside world has a peculiar habit of breaking in eventually and popping the intellectual bubbles within. As another example to the above, the late Freeman Dyson was ignored when he pointed out, <a target="_blank" href="https://e360.yale.edu/features/freeman_dyson_takes_on_the_climate_establishment">back in 2009</a>, that while climate activists shuttle between conferences on meeting carbon emission targets, China and India are keeping busy burning more coal than ever. Dyson may have moved on, but we don't believe that his point can be ignored forever.<a href="#r1" class="fn-btn fn-btn-bot">↩︎</a></p> </li> <li id="fn2"> <p>A fair question to ask is: What constitutes a technology field? Taking as a start a simple definition of technology as doing more with less, we believe that any field where some R&amp;D effort is undertaken to improve productivity is a technology sector. One surprising result of this definition is that Education, which accounts for over 5 percent of U.S. GDP spending at this point, would hardly qualify as a technology field, since so little of that spending goes to R&amp;D efforts to raise its productivity.<a href="#r2" class="fn-btn fn-btn-bot">↩︎</a></p> </li> <li id="fn3"> <p>According to the CDC, average life expectancy in the U.S. grew from 70.8 years in 1970 to a peak of 78.9 years in 2014, at the rate of 1.9 years per decade. By contrast, average life expectancy in the preceding four decades, from 1930 to 1970, grew at the rate of 2.7 years per decade, or 42 percent higher.<a href="#r3" class="fn-btn fn-btn-bot">↩︎</a></p> </li> <li id="fn4"> <p><em>Diagnosing the decline in pharmaceutical R&amp;D efficiency</em>, Jack Scannell, Alex Blanckley, Helen Boldon, and Brian Warrington, Nature, 2012 <a class="fn-ext-lnk" target="_blank" href="https://doi.org/10.1038/nrd3681">Learn more</a><span class="ext-aro-bs ext-aro-fo"></span><a href="#r4" class="fn-btn fn-btn-bot">↩︎</a></p> </li> <li id="fn5"> <p>It remains to be seen whether drug discovery resembles extractive industries like coal mining, where the low-hanging fruit argument might be somewhat valid, or whether it can actually turn into an engineering science. The former case would be worse if true, since extractive industries vastly outperform Pharma's record of drug discovery. The real cost of extracting a barrel of oil, or a ton of coal or most base metals, has gotten cheaper over time, while the cost of developing a new drug has ballooned exponentially.<a href="#r5" class="fn-btn fn-btn-bot">↩︎</a></p> </li> </ol> </div> <hr> <div class="section-headings"> <h2><a id="s2">Discovery</a></h2> <h3>Perspective is&nbsp;everything.</h3> </div> <p class="qst" id="q1">Your 2012 paper in Nature clearly showed the extent of the drug R&amp;D decline, and was a milestone in the debate over the future of Pharma. What moved you to write it? And how did you arrive at Eroom’s law?<a class="qst-lnk" href="#q1"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>Lorem ipsum dolor sit amet consectetur adipiscing elit duis nisi potenti, per hac phasellus felis nulla semper donec at erat, suspendie lacinia ut netus id mi maecenas mus metus. Aliquet pharetra cras magna odio condimentum erat, posuere integer inceptos purus imperdiet mauris, sodales convallis vehicula sit massa.</p> <p>Aliquet pharetra cras magna odio condimentum erat, amet consectetur adipiscing elit duis nisi potenti, per hac phasellus, dio condimentum erat, posuere integer incept.</p> <p>Consectetur adipiscing elit duis nisi potenti, per hac phasellus felis nulla semper donec at erat, suspendisse lacinia ut netus id mi mus metus. Aliquet pharetra cras magna odio condime erat, posuere integer inceptos purus imperdiet mauris, sodales convallis vehicula massa.</p> <p class="qst" id="q2">The Pharma industry was presumably well aware of its R&amp;D problem by the early 1980s. Many have alluded to it over the years, but none as vigorously as you did. Why do you think it took over three decades for such a paper to be written and published?<a class="qst-lnk" href="#q2"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>Lorem ipsum dolor sit amet consectetur adipiscing elit duis nisi potenti, per hac phasellus felis nulla semper donec at erat, suspendisse lacinia ut netus id mi maecenas mus metus. Aliquet pharetra cras magna odio condimentum erat, posuere integer inceptos purus imperdiet mauris, sodales convallis vehicula sit massa.</p> <p>Consectetur adipiscing elit duis nisi potenti, per hac phasellus felis nulla semper donec at erat, suspendisse lacinia ut netus id mi mus metus. Aliquet pharetra cras magna odio condime erat, posuere integer inceptos purus imperdiet mauris, sodales convallis vehicula massa.</p> <p>Aliquet pharetra cras magna odio condimentum erat, amet consectetur adipiscing elit duis nisi potenti, per hac phasellus, dio condimentum erat, posuere integer incept.</p> <p class="qst" id="q3">Judging by the widespread usage of Eroom’s law, your paper was a breakout success. What was the general response to your diagnosis? And how do you see the debate evolving in the years since?<a class="qst-lnk" href="#q3"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>Lorem ipsum dolor sit amet consectetur adipiscing elit duis nisi potenti, per hac phasellus felis nulla semper donec at erat, suspendisse lacinia ut netus id mi maecenas mus metus. Aliquet pharetra cras magna odio condimentum erat, posuere integer inceptos purus imperdiet mauris, sodales convallis vehicula sit massa.</p> <hr> <div class="section-headings"> <h2><a id="s3">Decline</a></h2> <h3>Parting&nbsp;on<br>bad&nbsp;terms.</h3> </div> <p class="qst" id="q4">Eroom’s law shows an 80 fold decline in drug R&amp;D productivity from the 1950s through the 2010s. What are the most important ways in which this staggering decline has changed the Pharma industry?<a class="qst-lnk" href="#q4"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>Lorem ipsum dolor sit amet consectetur adipiscing elit duis nisi potenti, per hac phasellus felis nulla semper donec at erat, suspendisse lacinia ut netus id mi maecenas mus metus. Aliquet pharetra cras magna odio condimentum erat, posuere integer inceptos purus imperdiet mauris, sodales convallis vehicula sit massa.</p> <p class="qst" id="q5">Marginal R&amp;D spending kept growing for decades, even as Pharma companies lost money on their investments. Was competition a big driver behind this? At what point does R&amp;D spending turn into a race to outspend everyone else?<a class="qst-lnk" href="#q5"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>Lorem ipsum dolor sit amet consectetur adipiscing elit duis nisi potenti, per hac phasellus felis nulla semper donec at erat, suspendisse lacinia ut netus id mi maecenas mus metus. Aliquet pharetra cras magna odio condimentum erat, posuere integer inceptos purus imperdiet mauris, sodales convallis vehicula sit massa.</p> <p class="qst" id="q6">The standard list of fixes to raise R&amp;D productivity tend to focus, by and large, on process efficiency and cost-cutting. Why haven’t these solutions been enough to stop and reverse Eroom’s law?<a class="qst-lnk" href="#q6"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>Lorem ipsum dolor sit amet consectetur adipiscing elit duis nisi potenti, per hac phasellus felis nulla semper donec at erat, suspendisse lacinia ut netus id mi maecenas mus metus. Aliquet pharetra cras magna odio condimentum erat, posuere integer inceptos purus imperdiet mauris, sodales convallis vehicula sit massa.</p> <p class="qst" id="q7">In the 1980s, people were still optimistic about recovering drug R&amp;D productivity. Today, investors have largely concluded that the decline is irreversible, and want to see R&amp;D spending scaled back in a big way. Are the investors right to be pessimistic?<a class="qst-lnk" href="#q7"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>Lorem ipsum dolor sit amet consectetur adipiscing elit duis nisi potenti, per hac phasellus felis nulla semper donec at erat, suspendisse lacinia ut netus id mi maecenas mus metus. Aliquet pharetra cras magna odio condimentum erat, posuere integer inceptos purus imperdiet mauris, sodales convallis vehicula sit massa.</p> <p class="qst" id="q8">Higher drug prices have driven more investment into R&amp;D in the past. What does the end of Eroom’s law mean for future drug pricing and drug discovery?<a class="qst-lnk" href="#q8"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>Lorem ipsum dolor sit amet consectetur adipiscing elit duis nisi potenti, per hac phasellus felis nulla semper donec at erat, suspendisse lacinia ut netus id mi maecenas mus metus. Aliquet pharetra cras magna odio condimentum erat, posuere integer inceptos purus imperdiet mauris, sodales convallis vehicula sit massa.</p> <hr> <div class="section-headings"> <h2><a id="s4">Alchemy</a></h2> <h3>Perspective is&nbsp;everything.</h3> </div> <p class="qst" id="q9">Incremental drug candidates need ever bigger and longer clinical trials to get FDA approval. Breakthrough drugs could presumably leapfrog ahead. What's keeping Pharma companies from pursuing bigger breakthroughs?<a class="qst-lnk" href="#q9"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>Lorem ipsum dolor sit amet consectetur adipiscing elit duis nisi potenti, per hac phasellus felis nulla semper donec at erat, suspendisse lacinia ut netus id mi maecenas mus metus. Aliquet pharetra cras magna odio condimentum erat, posuere integer inceptos purus imperdiet mauris, sodales convallis vehicula sit massa.</p> <p class="qst" id="q10">Over half of all new drug uses are discovered by field doctors from the existing pool of approved drugs. Biology reuses stuff, as you put it. How can we rehabilitate trial-and-error testing for drug discovery?<a class="qst-lnk" href="#q10"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>Lorem ipsum dolor sit amet consectetur adipiscing elit duis nisi potenti, per hac phasellus felis nulla semper donec at erat, suspendisse lacinia ut netus id mi maecenas mus metus. Aliquet pharetra cras magna odio condimentum erat, posuere integer inceptos purus imperdiet mauris, sodales convallis vehicula sit massa.</p> <p class="qst" id="q11">The statistical approach taken to drug discovery implies a poor understanding of human biochemistry. We don't know what will work, so we test 10<sup>7</sup> compounds and hope for a hit. Is this the best we can do? Could we turn drug discovery into an engineering science?<a class="qst-lnk" href="#q11"><svg viewBox="0 0 16 16" version="1.1" width="16" height="16"><path fill-rule="evenodd" d="M4 9h1v1H4c-1.5 0-3-1.69-3-3.5S2.55 3 4 3h4c1.45 0 3 1.69 3 3.5 0 1.41-.91 2.72-2 3.25V8.59c.58-.45 1-1.27 1-2.09C10 5.22 8.98 4 8 4H4c-.98 0-2 1.22-2 2.5S3 9 4 9zm9-3h-1v1h1c1 0 2 1.22 2 2.5S13.98 12 13 12H9c-.98 0-2-1.22-2-2.5 0-.83.42-1.64 1-2.09V6.25c-1.09.53-2 1.84-2 3.25C6 11.31 7.55 13 9 13h4c1.45 0 3-1.69 3-3.5S14.5 6 13 6z"></path></svg></a></p> <p>Lorem ipsum dolor sit amet consectetur adipiscing elit duis nisi potenti, per hac phasellus felis nulla semper donec at erat, suspendisse lacinia ut netus id mi maecenas mus metus. Aliquet pharetra cras magna odio condimentum erat, posuere integer inceptos purus imperdiet mauris, sodales convallis vehicula sit massa.</p> <hr class="hr-show"> </article> <div style="display:none"><span class="essay-nav-scroll"></span><span class="essay-btn-scroll"></span></div> </main> <footer id="footer-main" class="footer footer-light"> <div class="return-top"><a href="#top"><div class="bo-aro tp-aro u-aro"></div></a></div> <p>© 2019–<span id="current-year">2020</span> Refoundable LP</p> <ul> <li> <a href="/privacy">Privacy</a> </li> <li> <a href="/terms">Terms</a> </li> <li> <a href="/about#contact">Contact</a> </li> </ul> </footer> <script></script> <script>function stickyNav(){var e=document.getElementById("sticky-nav"),t=document.getElementsByClassName("sticky-btn");if(45<document.body.scrollTop||45<document.documentElement.scrollTop){e.classList.add("essay-nav-scroll");for(var s=0;s<t.length;s++)t[s].classList.add("essay-btn-scroll")}else for(e.classList.remove("essay-nav-scroll"),s=0;s<t.length;s++)t[s].classList.remove("essay-btn-scroll")}document.getElementById&&(onload=function(){setInterval("document.getElementById('current-year').firstChild.data = new Date().getFullYear()")})</script> <script>"serviceWorker"in navigator&&"refoundable.com"===window.location.hostname&&navigator.serviceWorker.register("/service-worker.js").then(function(e){console.log("ServiceWorker registration successful with scope: ",e.scope)}).catch(function(e){console.log("ServiceWorker registration failed: ",e)})</script> <script>!function(t,e){"function"==typeof define&&define.amd?define(function(){return e(t)}):"object"==typeof exports?module.exports=e:t.echo=e(t)}(this,function(u){"use strict";function d(t,e){if(function(t){return null===t.offsetParent}(t))return!1;var n=t.getBoundingClientRect();return n.right>=e.l&&n.bottom>=e.t&&n.left<=e.r&&n.top<=e.b}function c(){!i&&t||(clearTimeout(t),t=setTimeout(function(){s.render(),t=null},a))}var l,t,a,i,f,s={},h=function(){};return s.init=function(t){function e(t,e){return parseInt(t||e,10)}var n=(t=t||{}).offset||0,o=t.offsetVertical||n,r=t.offsetHorizontal||n;l={t:e(t.offsetTop,o),b:e(t.offsetBottom,o),l:e(t.offsetLeft,r),r:e(t.offsetRight,r)},a=e(t.throttle,250),i=!1!==t.debounce,f=!!t.unload,h=t.callback||h,s.render(),document.addEventListener?(u.addEventListener("scroll",c,!1),u.addEventListener("load",c,!1)):(u.attachEvent("onscroll",c),u.attachEvent("onload",c))},s.render=function(t){for(var e,n,o=(t||document).querySelectorAll("[data-echo], [data-echo-background]"),r=o.length,c={l:0-l.l,t:0-l.t,b:(u.innerHeight||document.documentElement.clientHeight)+l.b,r:(u.innerWidth||document.documentElement.clientWidth)+l.r},a=0;a<r;a++)n=o[a],d(n,c)?(f&&n.setAttribute("data-echo-placeholder",n.src),null!==n.getAttribute("data-echo-background")?n.style.backgroundImage="url("+n.getAttribute("data-echo-background")+")":n.src!==(e=n.getAttribute("data-echo"))&&(n.src=e),f||(n.removeAttribute("data-echo"),n.removeAttribute("data-echo-background")),h(n,"load")):f&&(e=n.getAttribute("data-echo-placeholder"))&&(null!==n.getAttribute("data-echo-background")?n.style.backgroundImage="url("+e+")":n.src=e,n.removeAttribute("data-echo-placeholder"),h(n,"unload"));r||s.detach()},s.detach=function(){document.removeEventListener?u.removeEventListener("scroll",c):u.detachEvent("onscroll",c),clearTimeout(t)},s})</script> <script>echo.init({offset:2500,throttle:250,unload:!1,callback:function(t,o){}})</script></body></html>